- Home
- LLY vs ABBV Comparison
LLY vs ABBV Comparison
Compare LLY & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LLY | ABBV |
|---|---|---|
| Founded | 1876 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 979.6B | 358.5B |
| IPO Year | 2007 | 2012 |
Fundamental Metrics
Financial Performance| Metric | LLY | ABBV |
|---|---|---|
| Price | $1,192.07 | $259.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 18 |
| Target Price | ★ $1,218.84 | $253.71 |
| AVG Volume (30 Days) | 2.1M | ★ 4.5M |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | 0.81% | ★ 3.39% |
| EPS Growth | ★ 95.99 | N/A |
| EPS | ★ 8.26 | 0.39 |
| Revenue | ★ $65,179,000,000.00 | $61,160,000,000.00 |
| Revenue This Year | $27.15 | $11.87 |
| Revenue Next Year | $16.04 | $8.12 |
| P/E Ratio | ★ $143.50 | $658.46 |
| Revenue Growth | ★ 44.70 | 8.57 |
| 52 Week Low | $623.78 | $187.62 |
| 52 Week High | $1,249.45 | $261.64 |
Technical Indicators
Market Signals| Indicator | LLY | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 56.56 | 65.69 |
| Support Level | $1,032.70 | $220.72 |
| Resistance Level | $1,249.45 | $261.30 |
| Average True Range (ATR) | 33.25 | 5.55 |
| MACD | -5.03 | -0.41 |
| Stochastic Oscillator | 50.76 | 89.77 |
Price Performance
Historical ComparisonAbout LLY Eli Lilly and Company
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.